Blood cancer, Acute myeloid leukemia, Cancer
KURAKura OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Ziftomenib + Induction Chemotherapy (7+3) in Blood cancer, Acute myeloid leukemia, Cancer. The expected timing is based on the latest available company guidance and may change.
KOMET-017-IC trial. 2/26/2025- Initiate trial in H2 2025. 9/29/25- First patient dosed. 11/04/25:- Phase 3 KOMET-017 intensive chemotherapy cohort first patient dosing reiterated; enrollment ongoing. 01/11/26:- Plan to advance KOMET-017-IC Phase 3 enrollment in newly diagnosed AML throughout 2026. 03/05/26:- KOMET-017 intensive 7+3 frontline AML cohort enrolling; first pivotal Phase 3 KOMET-017 topline results expected in 2028. 05/12/26:- KOMET-017 enrolling; EHA abstract online May 12, 2026. Accelerated FDA review potential in 2028. 05/12/26:- KOMET-017-IC Phase 3 global enrollment and site activation progressing well; topline 7+3 frontline AML results still expected 2028. 08/12/26:- KOMET-017 intensive cohort enrollment continues. First pivotal Phase 3 topline results are expected in 2028.
Verification
Confirm timing and program details against the company announcement or filing.